The Justice Department says it has reached a deferred prosecution agreement with Veloxis Pharmaceuticals under which the company is paying $46 million to resolve criminal and civil allegations that it paid kickbacks to induce prescriptions of its kidney transplant immunosuppressive drug Envarsus.

FDA releases the Form FDA-483 with three observations from a 2024 inspection at India’s MSN Life Sciences Unit II active pharmaceutical ingredient manufacturing facility.